Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.625    -0.025 (-3.85%)
Bid:
0.60
Ask:
0.65
Spread: 0.05 (8.333%)
Market Cap: £2.83m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Holding(s) in Company

20 Mar 2009 12:33

RNS Number : 2221P
Physiomics PLC
20 March 2009
 



Form TR-1 with annex. FSA Version 2.1 updated April 2007

For filings with the FSA include the annex

For filings with issuer exclude the annex 

TR-1: Notifications of Major Interests in Shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Physiomics plc

2. Reason for notification (yes/no)

An acquisition or disposal of voting rights

YES

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached 

NO

An event changing the breakdown of voting rights

NO

Other (please specify):______________

NO

3. Full name of person(s) subject to notification obligation:

Barclays PLC

4. Full name of shareholder(s) (if different from 3):

Barclays Stockbrokers Ltd

Gerrard Investment Management Ltd

5. Date of transaction (and date on which the threshold is crossed or reached if different):

18 March 2009

6. Date on which issuer notified:

19 March 2009

7. Threshold(s) that is/are crossed or reached:

7% to 8%

 

8: Notified Details

A: Voting rights attached to shares

Class/type of shares

If possible use ISIN code

GB00B04QT956

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

49,410,727

Number of voting rights

49,410,727

Number of shares

51,410,727

Number of voting rights

Percentage of voting rights

Direct

0

Indirect

51,410,727

Direct

Indirect

8.23%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ conversion period/date 

No. of voting rights that may be acquired (if the instrument exercised/converted)

Percentage of voting rights

N/A

N/A

N/A

N/A

N/A

Total (A+B)

Number of voting rights

Percentage of voting rights

51,410,727

8.23%

 

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable:

Barclays Capital Stockbrokers Ltd

Gerrard Investment Management Ltd

Proxy Voting:

10. Name of proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14 Contact name:

Geoff Smith

15. Contact telephone name:

020 7116 2913

For notes on how to complete form TR-1 please see the FSA website. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLBLFLKXBXBBF
Date   Source Headline
28th May 20267:00 amRNS-RHantavirus Translational Modelling Capability
27th May 20267:00 amRNSPhysiomics Awarded Multiple Contract Awards
26th May 20263:48 pmRNSHolding(s) in Company
21st May 20265:21 pmRNSHolding(s) in Company
15th May 20267:00 amRNSUpdate regarding CEO - Peter Sargent
12th May 20267:00 amRNSAppointment of Stewart Williams as Consultant
8th May 20267:00 amRNSStrategy Update
29th Apr 20266:15 pmRNSReplacement Result of Meeting and Board Changes
29th Apr 202611:00 amRNSResults of General Meeting and Board Changes
24th Apr 202610:30 amRNSReminder to Vote Against Resolutions
22nd Apr 20267:00 amRNSLaunch of Website for Requisitioned Meeting
17th Apr 20267:00 amRNSISS Voting Recommendation
14th Apr 20267:00 amRNSPhysiomics Awarded New Contract by Numab
8th Apr 20267:00 amRNSRequestioned GM and Investor Presentation
20th Mar 20269:45 amRNSHolding(s) in Company
20th Mar 20267:00 amRNSCancellation of General Meeting
18th Mar 20262:55 pmRNSResult of WRAP Retail Offer
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
16th Mar 20267:00 amRNSGeneral Meeting Request
16th Mar 20267:00 amRNSGeneral Meeting Request
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
11th Mar 20268:00 amRNSHolding(s) in Company
10th Mar 20267:01 amRNSWRAP Retail Offer for up to £49,999.98
16th Feb 20268:37 amRNSInterim Results
13th Feb 20262:23 pmRNSHolding(s) in Company
12th Feb 20267:00 amRNS-RPhysiomics Awarded New Contract
2nd Feb 202611:40 amRNSHolding(s) in Company
28th Jan 20267:00 amRNSPhysiomics Awarded New Contract by Numab
23rd Dec 20257:00 amRNSOptions Award
23rd Dec 20257:00 amRNSOptions Award
15th Dec 20257:00 amRNSPhysiomics Awarded Follow On Contract by UK Client
11th Dec 20257:00 amRNSPhysiomics Awarded New Contract by Numab
10th Dec 20257:00 amRNS-RPhysiomics Awarded New Contract by GARDP
8th Dec 20254:31 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNS-RPhysiomics Awarded Two New Contracts
3rd Dec 20257:00 amRNSBoard Changes
18th Nov 20253:43 pmRNSResult of AGM
17th Oct 20257:00 amRNSNotice of AGM
30th Sep 20257:00 amRNSChange of Registered Office
29th Sep 20257:00 amRNSAnnual Financial Report
22nd Sep 20257:00 amRNSNotice of Results and Investor Presentation
6th Aug 20257:00 amRNSFollow-on Contract with UK Biotech Client
16th Jul 20257:00 amRNSContract Award
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSPlatform Implementation and Partnership Expansion
1st Jul 20257:00 amRNSContract Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.